First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumours

Official Title

Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumours


The purpose of this study is to determine whether BMS-986218 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumours.

Trial Description

Primary Outcome:

  • Incidence of Adverse Events (AEs)
  • Incidence of Serious Adverse Events (SAEs)
  • Incidence of AEs meeting protocol- defined dose-limiting toxicity (DLT) criteria
  • Incidence of AEs leading to discontinuation
  • Incidence of death
  • Objective Response Rate (ORR)
  • Median Duration of Response (mDOR)
  • Progression Free Survival Rate (PFSR) by Response Evaluation Criteria in Solid Tumours (RECIST) v1.1
Secondary Outcome:
  • ORR
  • mDOR
  • PFSR by RECIST v1.1
  • Incidence of anti-drug antibody (ADA)
  • Maximum observed plasma concentration (Cmax)
  • Time of maximum observed plasma concentration (Tmax)
  • Trough observed serum concentration (Ctrough)

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society